Crispr Therapeutics shares tumble after significant earnings miss
OAK RIDGE, TN - Daxor Corporation (NASDAQ:DXR), known for its blood volume measurement technology, has announced the submission of its latest blood volume analyzer to the FDA today. The company's stock, currently trading near $7.34, has shown resilience with a slight YTD gain of 0.3% despite broader market volatility. According to InvestingPro data, DXR typically moves independently of market trends, with a beta of -0.06. The new device, named Daxor BVA, is designed to enhance fluid management in healthcare settings by providing rapid and precise blood volume analysis.
The Daxor BVA system is a significant improvement over the company's previous model, the BVA-100™. It boasts a processing time that is three times faster, streamlined operation, portability, and the capability for point-of-care analysis. These advancements are expected to facilitate the incorporation of sophisticated blood volume diagnostics into routine clinical practices.
Daxor's CEO and President, Michael Feldschuh, stated that the new analyzer was developed under a U.S. Department of Defense contract and is set to deliver unmatched speed, accessibility, and accuracy in blood volume management. Feldschuh emphasized the potential for the device to improve medical care and patient outcomes significantly. While the company maintains profitability with a 100% gross margin, InvestingPro analysis indicates analysts expect sales challenges ahead, with a projected 16% revenue decline for FY2025.
Daxor Corporation markets the BVA-100®, the only FDA-cleared diagnostic blood test that quantifies blood volume status and composition in comparison to patient-specific norms. The company has conducted over 65,000 tests across leading U.S. hospital centers, contributing to improved hospital performance metrics in various medical conditions, including heart failure and critical care.
The company is actively involved in ongoing trials for heart failure treatment with NIH support and is developing analyzers to enhance combat casualty care in collaboration with the U.S. Department of Defense. Daxor's mission is to advance healthcare through optimal fluid management using blood volume analysis.
The submission of the Daxor BVA system to the FDA marks a promising step in the company's continued innovation in diagnostic technologies. This information is based on a press release statement. With analyst price targets ranging from $22 to $25, significantly above current trading levels, investors seeking deeper insights can access comprehensive analysis and additional ProTips through InvestingPro's detailed research reports, available as part of its coverage of over 1,400 US equities.
In other recent news, Daxor Corporation reported a remarkable 116.5% increase in revenue year-over-year for Q4 2024, marking a significant milestone as the company also achieved cash flow breakeven in Q1 2025. This growth is attributed to innovative product developments and strategic market expansion efforts. Daxor is also advancing its next-generation blood volume analyzer, with plans to resubmit it for FDA approval, aiming for a 510(k) clearance. The company anticipates filing for a CLIA waiver later in 2025, projecting significant market interest in its new system. Additionally, Daxor's Blood Volume Analyzer (BVA-100®) garnered attention at the American College of Cardiology's Annual Scientific Session, highlighting its potential advantages over traditional methods for heart failure patients. Analysts have shown interest in the company's developments, with the earnings report reflecting positive investor sentiment. Furthermore, Daxor is actively pursuing strategic partnerships and expanding its market presence, including efforts to enhance combat casualty care for the U.S. Department of Defense.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.